An Insider Erin Mcglaughlin Acquired 2 shares of The York Water Company (YORW); Atara Biotherapeutics (ATRA) Shorts Decreased By 7.26%

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Logo

Atara Biotherapeutics Inc (NASDAQ:ATRA) had a decrease of 7.26% in short interest. ATRA’s SI was 4.82 million shares in April as released by FINRA. Its down 7.26% from 5.19 million shares previously. With 1.37M avg volume, 4 days are for Atara Biotherapeutics Inc (NASDAQ:ATRA)’s short sellers to cover ATRA’s short positions. The SI to Atara Biotherapeutics Inc’s float is 32.01%. The stock decreased 4.56% or $1.85 during the last trading session, reaching $38.75. About 235,274 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 88.73% since April 16, 2017 and is uptrending. It has outperformed by 77.18% the S&P500.

Since October 26, 2017, it had 0 insider buys, and 21 sales for $14.60 million activity. The insider Ciechanover Isaac E. sold 4,400 shares worth $64,438. $464,210 worth of stock was sold by Turner Heather D on Friday, February 9. 100,203 shares were sold by Clark Mitchall G., worth $3.80M on Tuesday, March 27. 6,000 Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares with value of $242,460 were sold by MCGRATH JOHN. Gallagher Carol Giltner also sold $55,010 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares. Haqq Christopher also sold $729,265 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, March 26.

Investors sentiment decreased to 1.42 in Q4 2017. Its down 0.12, from 1.54 in 2017Q3. It dived, as 9 investors sold Atara Biotherapeutics, Inc. shares while 17 reduced holdings. 12 funds opened positions while 25 raised stakes. 27.87 million shares or 6.54% more from 26.16 million shares in 2017Q3 were reported. Moreover, State Street has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 443,821 shares. Pacific Heights Asset Mngmt Limited Liability Corp reported 25,000 shares or 0.04% of all its holdings. Goldman Sachs Inc reported 20,266 shares. Great West Life Assurance Can holds 1,654 shares or 0% of its portfolio. Alps Advsr Inc invested in 0% or 33,904 shares. Nebraska-based Ameritas Investment Ptnrs has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Alliancebernstein Ltd Partnership has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Vident Investment Advisory Limited Co reported 85,810 shares or 0.07% of all its holdings. Citigroup, New York-based fund reported 229 shares. Alyeska Invest Gru L P holds 0.03% or 174,868 shares in its portfolio. Envestnet Asset holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1,011 shares. Voya Mngmt Limited Liability Corporation invested in 11,813 shares. Royal Bancorp Of Canada holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 133 shares. Fmr Limited Liability Company, a Massachusetts-based fund reported 1.83M shares. Amer Intll Gru invested in 0% or 18,016 shares.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.67 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Among 10 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Atara Biotherapeutics had 27 analyst reports since September 9, 2015 according to SRatingsIntel. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Buy” rating given on Thursday, August 31 by Jefferies. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, January 30. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The company was initiated on Friday, September 25 by JMP Securities. The company was reinitiated on Monday, October 24 by Jefferies. On Tuesday, December 15 the stock rating was maintained by JMP Securities with “Market Outperform”. As per Wednesday, January 3, the company rating was upgraded by Citigroup. The rating was initiated by Canaccord Genuity with “Buy” on Wednesday, September 9. The firm has “Neutral” rating given on Wednesday, November 18 by Goldman Sachs. William Blair maintained the shares of ATRA in report on Friday, April 6 with “Buy” rating.

Since January 16, 2018, it had 24 buys, and 0 selling transactions for $33,921 activity. 7 shares were bought by Rasmussen Steven R, worth $227. $130 worth of The York Water Company (NASDAQ:YORW) was bought by Poff Matthew E. NEWCOMER ROBERT P bought $877 worth of stock. HINES JEFFREY R bought $5,618 worth of The York Water Company (NASDAQ:YORW) on Wednesday, January 17. 52 shares valued at $1,689 were bought by GANG MICHAEL W on Tuesday, January 16. $487 worth of The York Water Company (NASDAQ:YORW) was bought by BRACEY VERNON L on Wednesday, January 17. The insider Strine John H bought $1,299.

The stock increased 3.10% or $0.975 during the last trading session, reaching $32.475. About 15,120 shares traded. The York Water Company (NASDAQ:YORW) has declined 10.98% since April 16, 2017 and is downtrending. It has underperformed by 22.53% the S&P500.

The York Water Company impounds, purifies, and distributes drinking water. The company has market cap of $418.31 million. It owns and operates three wastewater collection systems and two wastewater treatment systems; and has two reservoirs comprising Lake Williams and Lake Redman, which together hold up to approximately 2.2 billion gallons of water. It has a 32.15 P/E ratio. The firm also has a 15-mile pipeline from the Susquehanna River to Lake Redman; and owns seven wells that supply approximately 366,000 gallons of water per day to its clients in Carroll Valley Borough and Cumberland Township, Adams County.

The director of York Water Co, Erin Mcglaughlin a few days ago paid closely $56 USD on 2 shares in the York Water Co company at an approx. $28.0 per share. It seems she is very active lately as in the last 30 days, she quietly obtained additional 32 shares of the company, worth $991 USD. A report free at your disposal here revealed this trade activity. It was revealed on April 16, 2018 and filled with U.S. SEC. Currently, Erin Mcglaughlin has 376 shares or around 0.00% of the Company’s market capitalization.

The York Water Company (NASDAQ:YORW) Institutional Positions Chart